ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /反応

Potassium Carbonate → 2-[4-(1-Hydroxy-1-methylethyl)phenyl]-5-{[6-(2-hydroxy-1-morpholin-4-ylethyl)pyridin-2-yl]amino}-1,3-thiazole-4-carboxamide

HRID 2060598
印刷

反応式

HRID 2060598 の反応式
[NH2:1][C:2]1[S:6][C:5]([C:7]2[CH:12]=[CH:11][C:10]([C:13]([OH:16])([CH3:15])[CH3:14])=[CH:9][CH:8]=2)=[N:4][C:3]=1[C:17]([NH2:19])=[O:18].CC(C1C=C(C(C)C)C(C2C=CC=CC=2P(C2CCCCC2)C2CCCCC2)=C(C(C)C)C=1)C.C(=O)([O-])[O-].[K+].[K+].Br[C:61]1[N:66]=[C:65]([CH:67]([N:70]2[CH2:75][CH2:74][O:73][CH2:72][CH2:71]2)[CH2:68][OH:69])[CH:64]=[CH:63][CH:62]=1>C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.C1C=CC(/C=C/C(/C=C/C2C=CC=CC=2)=O)=CC=1.[Pd].[Pd]>[OH:16][C:13]([C:10]1[CH:9]=[CH:8][C:7]([C:5]2[S:6][C:2]([NH:1][C:61]3[CH:62]=[CH:63][CH:64]=[C:65]([CH:67]([N:70]4[CH2:75][CH2:74][O:73][CH2:72][CH2:71]4)[CH2:68][OH:69])[N:66]=3)=[C:3]([C:17]([NH2:19])=[O:18])[N:4]=2)=[CH:12][CH:11]=1)([CH3:15])[CH3:14]
参加物実験手順後処理出典と根拠反応ノート

参加物

6

反応物 4

HCID 11430Potassium CarbonateHCID 111557942-Dicyclohexylphosphino-2',4',6'-triisoprophylbiphenylHCID 583352645-Amino-2-[4-(1-hydroxy-1-methylethyl)phenyl]-1,3-thiazole-4-carboxamideHCID 583352752-(6-Bromopyridin-2-yl)-2-morpholin-4-ylethanol

生成物 1

HCID 574828002-[4-(1-Hydroxy-1-methylethyl)phenyl]-5-{[6-(2-hydroxy-1-morpholin-4-ylethyl)pyridin-2-yl]amino}-1,3-thiazole-4-carboxamide

試薬・触媒・溶媒 1

HCID 9811564Bis(dibenzylideneacetone)palladium触媒

実験手順

A sealed tube was charged with a stir bar, 5-amino-2-[4-(1-hydroxy-1-methylethyl)phenyl]-1,3-thiazole-4-carboxamide (Example 5, Step 3) (60 mg, 0.22 mmol), Pd2(dba)3 (5.9 mg, 6.5 μmol), X-PHOS (15.5 mg, 0.032 mmol), and potassium carbonate (33 mg, 0.24 mmol). The tube was evacuated and backfilled with argon three times. 2-(6-bromopyridin-2-yl)-2-morpholin-4-ylethanol (Example 3, Step 1) (62 mg, 0.22 mmol) was placed in a separate vial which was also evacuated and backfilled with argon three times. Fully degassed tert-amyl alcohol (500 μl) was added to 2-(6-bromopyridin-2-yl)-2-morpholin-4-ylethanol and the resulting solution was transferred to the sealed tube via syringe. The tube was then sealed and placed in an oil bath at 100° C. and stirred overnight. The reaction was cooled to room temperature, diluted with ethyl acetate, and washed with saturated aqueous sodium bicarbonate (2×) and brine (2×). The organic layer was dried over magnesium sulfate, filtered, and concentrated in vacuo. Purification was performed by reverse phase HPLC (10-100% acetonitrile/water+0.05% TFA modifier, monitoring at 230 nM). Desired fractions were poured into a mixture of ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer was extracted, dried over magnesium sulfate, filtered, and concentrated in vacuo to afford the title compound as a light yellow powder. 1H NMR (500 MHz, d6-DMSO) δ 11.25 (s, 1H), 7.84 (d, 2H), 7.70 (s, 1H), 7.68 (t, 1H), 7.59 (s, 1H), 7.55 (d, 2H), 7.05 (d, 1H), 6.92 (d, 1H), 5.08 (s, 1H), 4.51 (t, 1H), 3.98 (m, 2H), 3.65 (t, 1H), 3.53 (m, 4H), 3.75 (m, 4H), 3.42 (s, 6H). LRMS (APCI) calc'd for (C24H30N5O4S) [M+H]+, 484.2; found 484.1.

後処理

  1. additionA sealed tube was charged with a stir bar
  2. customThe tube was evacuated
  3. customwas also evacuated
  4. additionFully degassed tert-amyl alcohol (500 μl) was added to 2-(6-bromopyridin-2-yl)-2-morpholin-4-ylethanol
  5. customthe resulting solution was transferred to the sealed tube via syringe
  6. customThe tube was then sealed
  7. customplaced in an oil bath at 100° C.
  8. additiondiluted with ethyl acetate
  9. washwashed with saturated aqueous sodium bicarbonate (2×) and brine (2×)
  10. dry with materialThe organic layer was dried over magnesium sulfate
  11. filtrationfiltered
  12. concentrationconcentrated in vacuo
  13. customPurification
  14. additionDesired fractions were poured into a mixture of ethyl acetate and saturated aqueous sodium bicarbonate
  15. extractionThe organic layer was extracted
  16. dry with materialdried over magnesium sulfate
  17. filtrationfiltered
  18. concentrationconcentrated in vacuo

出典と根拠

ORDレコード
ord-00aa7fb04f0e4dbe8a7df5a82fe10bef
出典データセット
uspto-grants-2012_10
DOI
10.6084/m9.figshare.5104873.v1
特許番号
US08278335B2

反応ノート

このページの内容参加物実験手順後処理出典と根拠反応ノート